logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > CC-486 for maintenance therapy in acute myeloid leukaemia

< Back

CC-486 for maintenance therapy in acute myeloid leukaemia

Drugs

Cancer and Palliative Care

October 2020


CC-486 is being developed as a maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy (IC), and who are not candidates for or choose not to proceed to hematopoietic stem cell transplantation (HSCT). AML is a rapidly growing cancer of the blood and bone marrow caused by a DNA mutation in the stem cells. Although most patients with newly diagnosed AML will respond to IC, responses are often short-lived and overall survival is poor. Further post-remission therapy is necessary to achieve a durable remission.
CC-486 is a drug that can be incorporated into the genetic material of cells instead of their natural building-block, cytidine. It is thought to work by altering the way the cell turns genes on and off and interfering with the production of new RNA and DNA, leading to the death of rapidly dividing cancer cells that are not responsive to normal growth control mechanism. Its oral route of administration avoids injection-site reactions and may enhance patient convenience. The benefits of extended CC-486 dosing and long‐term treatment are likely related to the impact on hypomethylation, potentially enhancing clinical activity of the drug by increasing exposure to cycling malignant cells. If licensed, CC-486 will provide an additional maintenance therapy options for older AML patients who achieved CR or CRi following IC and who are not candidates for or choose not to proceed to HSCT.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts